| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/15/1995 | WO1995015743A1 Cosmetic and/or pharmaceutical preparations with improved skin feel |
| 06/15/1995 | WO1995006129A3 Transfection process |
| 06/15/1995 | CA2178620A1 Microsphere drug delivery system |
| 06/15/1995 | CA2178477A1 Pretargeting methods and compounds |
| 06/15/1995 | CA2178476A1 Pretargeting methods and compounds |
| 06/15/1995 | CA2177588A1 Transdermal delivery device containing (s)-3methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole |
| 06/15/1995 | CA2177495A1 Cysteine protease inhibitors containing heterocyclic leaving groups |
| 06/15/1995 | CA2137533A1 Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof |
| 06/14/1995 | EP0657463A1 Phospholipid derivative and vesicle comprising the same |
| 06/14/1995 | EP0657176A2 Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| 06/14/1995 | EP0657175A2 Vaccine comprising autologous epidermal growth factor and use thereof |
| 06/14/1995 | EP0657164A1 Pharmaceutical compositions containing staurosphorine derivatives |
| 06/14/1995 | EP0657161A1 Pharmaceutical granulate containing steroids |
| 06/14/1995 | EP0656950A1 Tat-derived transport polypeptides |
| 06/14/1995 | EP0656889A1 9-chloroprostaglandin esters and amides and their use in the preparation of drugs |
| 06/14/1995 | EP0656883A1 Cationic lipids |
| 06/14/1995 | EP0656777A1 Ready-to-inject azosemide solutions. |
| 06/14/1995 | EP0656775A1 Sustained release tablets containing bupropion |
| 06/14/1995 | DE4342232A1 Solid prostaglandin E1 formulations |
| 06/14/1995 | CA2136118A1 Pharmaceutical composition for controlled release |
| 06/14/1995 | CA2111320A1 Pharmaceutical granulate |
| 06/13/1995 | US5424471 Crystalline amifostine compositions and methods of the preparation and use of same |
| 06/13/1995 | US5424469 Process for preparing polyglycerol fatty acid ester mixtures and use in cosmetic, pharmeceutical and chemical preparations |
| 06/13/1995 | US5424301 Cognition activators |
| 06/13/1995 | US5424298 Topical powder compositions containing a cyclic AMP derivative |
| 06/13/1995 | US5424297 Hypotensive agents |
| 06/13/1995 | US5424289 Solid formulations of therapeutic proteins for gastrointestinal delivery |
| 06/13/1995 | US5424288 Prolonging time therapeutic agent remains in tumor |
| 06/13/1995 | US5424208 Contacting connective tissue containing viable cells with collagenase and chymopapain to hydrolyze the connective tissue |
| 06/13/1995 | US5424078 Aqueous ophthalmic formulations and methods for preserving same |
| 06/13/1995 | US5424076 Sustained release |
| 06/13/1995 | US5424075 Delivery system for enhanced onset and increased potency |
| 06/13/1995 | US5424070 Transparent clear stick composition |
| 06/13/1995 | US5424067 Water-immiscible oily phase, emulsifying system, and aqueous antigen; nontoxic |
| 06/13/1995 | US5423739 Device and method for iontophoretic drug delivery |
| 06/13/1995 | EP0724449A4 Preservative for pharmaceutical products |
| 06/10/1995 | CA2137426A1 Diffusion-osmotic controlled drug-release pharmaceutical compositions and process for preparing same |
| 06/10/1995 | CA2137206A1 Glucagon-like insulinotropic peptides, compositions and methods |
| 06/09/1995 | CA2136590A1 Recombinant genes expressing pp14 |
| 06/08/1995 | WO1995015377A1 Plant arabinogalactan protein (agp) genes |
| 06/08/1995 | WO1995015343A1 POLY-β-1→4-N-ACETYLGLUCOSAMINE |
| 06/08/1995 | WO1995015341A1 Antibody against carcinoembryonic antigen (cea) |
| 06/08/1995 | WO1995015183A1 Hirudin conjugates from hirudin and lipophilic compounds |
| 06/08/1995 | WO1995015178A1 Vibrio cholerae bengal serogroup-0139 capsular polysaccharide, protein conjugates thereof and antibodies induced thereby |
| 06/08/1995 | WO1995015173A1 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| 06/08/1995 | WO1995015171A1 A 46 Kd HUMAN MILK FAT GLOBULE ANTIGEN |
| 06/08/1995 | WO1995015170A1 Use of dimeticone for treating constipation |
| 06/08/1995 | WO1995015165A1 Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injuri |
| 06/08/1995 | WO1995015155A1 Taste masked composition containing a drug/polymer complex |
| 06/08/1995 | WO1995015152A1 External preparation |
| 06/08/1995 | WO1995015118A1 Gas microspheres for topical and subcutaneous application |
| 06/08/1995 | DE4437502A1 Conjugates of hirudin with lipophilic cpds. |
| 06/08/1995 | DE4341478A1 Antitumour compsn. comprising starch particles, cytostatic and contrast agent |
| 06/08/1995 | DE4341114A1 Emulsions comprising non-aqueous phase dispersed in oil phase |
| 06/08/1995 | CA2177991A1 A 46 kd human milk fat globule antigen |
| 06/08/1995 | CA2177953A1 Plant arabinogalactan protein (agp) genes |
| 06/08/1995 | CA2177825A1 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| 06/08/1995 | CA2177822A1 Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injuri |
| 06/08/1995 | CA2177721A1 Taste masked composition containing a drug/polymer complex |
| 06/08/1995 | CA2177713A1 Gas microspheres for topical and subcutaneous application |
| 06/08/1995 | CA2177584A1 Antibody against carcinoembryonic antigen (cea) |
| 06/08/1995 | CA2176967A1 Hirudin conjugates from hirudin and lipophilic compounds |
| 06/07/1995 | EP0656426A2 New Method of making crystalline sugar and products resulting therefrom |
| 06/07/1995 | EP0656367A1 Method and composition for cancer therapy and for prognosticating responses to cancer theraphy |
| 06/07/1995 | EP0656215A1 Glycosaminoglycan-synthetic polymer conjugates |
| 06/07/1995 | EP0656214A1 Clear, chemically-modified collagensynthetic polymer conjugates for ophthalmic applications |
| 06/07/1995 | EP0656213A1 Treatment of conditions and disease |
| 06/07/1995 | EP0656212A1 Liquid compositions containing cyclosporin and process for their preparation |
| 06/07/1995 | EP0656211A1 Stable lyophilized thiotepa composition |
| 06/07/1995 | EP0656207A1 Non-chlorofluorocarbon aerosol formulations |
| 06/07/1995 | EP0656206A1 Non-chlorofluorocarbon aerosol formulations |
| 06/07/1995 | EP0656205A1 Non-chloroflurocarbon aerosol formulations |
| 06/07/1995 | EP0656115A1 Improved detection and therapy of lesions with biotin/avidin conjugates |
| 06/07/1995 | EP0656037A1 Metal-mediated cross-coupling with ring-metalated porphyrins |
| 06/07/1995 | EP0656026A1 Polyarylates containing derivatives of the natural amino acid l-tyrosine |
| 06/07/1995 | EP0656015A1 New nimesulide salt cyclodextrin inclusion complexes |
| 06/07/1995 | EP0655946A1 Utilization of a transacylation reaction between an esterified polysaccharide and a polyaminated or polyhydroxylated substance for fabricating microparticles, microparticles thus obtained, methods and compositions containing them |
| 06/07/1995 | EP0655929A1 Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines |
| 06/07/1995 | EP0655917A1 Crystalline amifostine compositions and methods for the preparation and use of same |
| 06/07/1995 | EP0655911A1 Ophthalmological preparation |
| 06/07/1995 | EP0454783B1 Site specific in-vivo activation of therapeutic drugs |
| 06/07/1995 | CN1103316A Cyclodextrin and polymer-based drug delivery system |
| 06/07/1995 | CN1103291A Preparation for skin and mucous membrane |
| 06/07/1995 | CN1103290A Pharmaceutical preparation |
| 06/07/1995 | CN1103289A Opioid formulations having extended controlled release |
| 06/07/1995 | CN1103288A Local anaesthetic and its preparing method |
| 06/07/1995 | CA2137319A1 Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| 06/06/1995 | US5422379 Highly branched cascade compounds; radioimaging, drug delivery |
| 06/06/1995 | US5422376 Synthetic viscoelastic material for ophthalmic applications |
| 06/06/1995 | US5422371 Contacting a cell with a fatty acid or fatty alcohol to prevent reduction of testosterone to 5a-dihydrotestosterone |
| 06/06/1995 | US5422370 Method of using 2-hydroxypropanoic acid (lactic acid) for the treatment of wrinkles |
| 06/06/1995 | US5422363 Therapy of cancer, diabetes and vision disorders |
| 06/06/1995 | US5422361 Stable cream and lotion bases for lipophilic drug compositions |
| 06/06/1995 | US5422347 Fungicides, hair and skin disorders |
| 06/06/1995 | US5422261 Pure, aqueous, nontoxic mixtures of proteolytic enzymes in buffered physiologically compatible electrolyte solutions |
| 06/06/1995 | US5422258 Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils |
| 06/06/1995 | US5422123 Comprising a core of drug, swellable polymer and gellable polymer and a cover or support of swellable and gellable polymers; noncracking and -flaking |
| 06/06/1995 | US5422118 Transdermal administration of amines with minimal irritation and high transdermal flux rate |
| 06/06/1995 | US5422116 Administering to eye homogeneous liquid aqueous composition containing chitosan as release rate controlling agent |
| 06/06/1995 | US5422111 Polyose/fatty acid complex product with a high fatty acid content, use as an emulsifier or moisturizer and emulsifying or moisturizing composition in which it is present |